Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2014 ACR/ARHP Annual Meeting: Alive and Growing

Susan Bernstein  |  Issue: February 2015  |  February 1, 2015

Alive and growing

BOSTON—Bone disorders, whether in the tissue or molecular pathways, are actively involved in the development of osteoarthritis (OA) pain and progression.

“We know that bone is a live organ. It is not static. It always responds to mechanical loading,” said Xu Cao, PhD, director of the Center for Musculoskeletal Research at Johns Hopkins School of Medicine in Baltimore, Md. Dr. Cao and two other researchers spoke about The Role of Bone in the Pathogenesis of Osteoarthritis at the ACR/ARHP Annual Meeting in Boston on Nov. 17, 2014.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers want to know more about the various players in bone and cartilage destruction in OA, the panelists said.

Lesions & Pain

Pain is common in OA but not well understood by rheumatologists, but identifying the role of bone marrow lesions in OA pain may drive more effective management of this problem, said David T. Felson, MD, MPH, professor of medicine and public health at Boston University and the University of Manchester in the U.K.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Bone marrow lesions are one likely culprit for fluctuating and worsening OA pain, especially in patients with knee malalignment, Dr. Felson said. “These lesions are more strongly related with dynamic than static malalignment,” he said.

Histologically, bone marrow lesions reflect bone that has undergone trauma, with microfractures and evidence of injury and repair. Bone marrow lesions are a major risk factor for knee OA progression. They can be caused by other structural lesions that increase focal load on the bone, including knee malalignment, meniscal tears, and/or cartilage loss in the knee joint, Dr. Felson said.

Bone marrow lesions may fluctuate in a short timeframe in knees with OA, even over six weeks. Bone marrow, subchondral bone and, especially, the periosteum are the “structures in the bone that are the most innervated with pain fibers,” Dr. Felson said. This rich supply of nerves sets the stage, and bone marrow lesions clearly play a starring role in knee OA pain, he added. “Knee pain severity decreases with bone marrow shrinkage or resolution. It clearly is a causal agent of OA pain.”

Patellar braces may help ease pain and improve patellofemoral bone marrow lesions in OA patients, even in just six weeks, Dr. Felson said. “Bone marrow lesions are a good structural target for treatment.”

‘Knee pain severity decreases with bone marrow shrinkage or resolution. It clearly is a causal agent of OA pain.’

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2014 ACR/ARHP Annual MeetingAC&RAssociation of Rheumatology Professionals (ARP)BernsteinboneOsteoarthritisResearch

Related Articles

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

    A Passion for Multidisciplinary Collaboration

    February 3, 2012

    Through teamwork, David T. Felson, MD, MPH, has advanced understanding and treatment of rheumatic diseases

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    New Treatments Needed to Prevent Fractures in Osteoporosis

    June 1, 2014

    Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences